Serum Uric Acid in Acute Coronary Syndromes

Alka Flora Marak¹, Narmada Thongam², Davina Hijam¹, Oinam Prabita Devi¹, Salam Rojen Singh⁵, Taruni Ng⁶

ABSTRACT

Introduction: Uric acid (urate), an organic compound of carbon, nitrogen, oxygen and hydrogen has been thought to be protective against ageing, oxidative stress and oxidative cell injury owing to its oxidant property. Recent epidemiological and clinical evidences suggest that hyperuricaemia might be a risk factor for cardiovascular disease where enhanced oxidative stress plays an important pathophysiological role. The study is taken up to determine serum uric acid levels in Acute Coronary Syndromes (ACS) and to compare the incidence of complications in hyperuricaemic and normouricaemic acute coronary syndrome patients.

Material and Methods: A prospective cohort study was conducted in the Department of Medicine in collaboration with Department of Biochemistry, RIMS, Imphal from October 2014 to September 2016, among 73 normouricaemic ACS patients and 73 hyperuricaemic ACS patients. Clinical and anthropometric data were taken from each subject. Laboratory evaluation involves serum uric acid by enzymatic colorimetric method.

Results: The mean serum uric acid level in the study population was 5.96 ± 1.88 mg/dl. Arrhythmias occurred in 27.4% of hyperuricaemic patients and 5.5% of normouricaemic patients. It is observed that 27 patients developed congestive cardiac failure (CCF), out of which 17 patients (22.3%) were hyperuricaemic and 10 patients (13.7%) were normouricaemic. Pulmonary edema (PE) was observed in 35 hyperuricaemic and 28 normouricaemic patients (47.9% and 38.4% respectively).

Conclusions: Complications of ACS such as arrhythmias, CCF and PE occurred more frequently in hyperuricaemic and normouricaemic acute coronary syndrome patients. Thus, it can be concluded that serum uric acid level can be considered a suitable marker for predicting ACS-related future adverse events.

Keywords: Acute Coronary Syndrome, Arrhythmia, Congestive Cardiac Failure, Hyperuricaemia, Pulmonary Edema.

INTRODUCTION

Ischaemic heart disease (IHD) causes more deaths and disability and incurs greater economic costs than any other illness in the developed world. Population subgroups that appear to be particularly affected are men in South Asian countries, especially India and the Middle East. In light of the projection of large increases in IHD throughout the world, IHD is likely to become the most common cause of death worldwide by 2020.¹

Patients with ischaemic heart disease fall into two large groups: patients with Coronary Artery Disease (CAD) who most commonly present with stable angina and patients with Acute Coronary Syndromes (ACS). These include patients with acute myocardial infarction with ST segment elevation (STEMI) on their presenting electrocardiogram and those with non ST elevation ACS (NSTE-ACS) which include patients with non ST elevation myocardial infarction (NSTEMI) who have myocyte necrosis, and, those with unstable angina (UA) who do not.²

Uric acid (urate), an organic compound of carbon, nitrogen, oxygen and hydrogen, is the final oxidation product of purine metabolism, and its elevated levels reflect increased xanthine oxidase activity. For decades it has been hypothesised that the oxidant properties of uric acid might be protective against ageing, oxidative stress and oxidative cell injury. However, recent epidemiological and clinical evidences suggest that hyperuricaemia might be a risk factor for cardiovascular disease where enhanced oxidative stress play an important pathophysiological role.³ It has been recently reported that serum uric acid is an independent predictor of mortality for patients with coronary artery disease (CAD) and morbidity, including acute myocardial infarction (AMI) or congestive heart failure (CHF).⁴,⁵,⁶,⁷

Hyperuricaemia is present frequently in patients with symptomatic heart failure, acute coronary syndromes, arterial hypertension, and atrial fibrillation.⁸,⁹,¹⁰ It has been postulated that serum uric acid plays a pivotal role in the pathogenesis of cardiovascular diseases affecting xanthine oxidase pathway that contributes to the production of reactive oxygen species with deterioration of cell membranes¹¹. Reactive oxygen species contribute to vascular oxidative stress and endothelial dysfunction, which are associated with the risk of atherosclerosis, damages of both cardiomyocytes and

¹PGT, Department of Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, ²Assistant Professor, Department of Biochemistry, Jawaharlal Nehru Institute of Medical Sciences, Imphal, Manipur, ³Assistant Professor, Department of Biochemistry, Regional Institute of Medical Sciences, Imphal, Manipur, ⁴Senior Resident, Department of Biochemistry, Regional Institute of Medical Sciences, Imphal, Manipur, ⁵Department of Biochemistry, Regional Institute of Medical Sciences, Imphal, Manipur, ⁶Professor and Head, Department of Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, India

Corresponding author: Narmada Thongam, Department of Biochemistry, Jawaharlal Nehru Institute of Medical Sciences, Imphal, Manipur, India

How to cite this article: Alka Flora Marak, Narmada Thongam, Davina Hijam, Oinam Prabita Devi, Salam Rojen Singh, Taruni Ng. Serum Uric Acid in Acute Coronary Syndromes. International Journal of Contemporary Medical Research 2019;6(3):C1-C5.

DOI: http://dx.doi.org/10.21276/ijcmr.2019.6.3.11
vascular endothelium inducing disturbances of myocardial contractility and vasoconstriction. The increase in serum uric acid in patients with cardiovascular disease may reflect a compensatory mechanism to counter the oxidative stress that occurs with tissue hypoxia, thus, the higher levels of uric acid corresponding to high risk may reflect response to tissue injury, whereas the higher risk at lower levels of uric acid levels may be the result of decreased antioxidant capacity.

Evidence for involvement of uric acid in cardiovascular disease is extensive, and so are the controversies surrounding the interpretation of the data. This study has been taken up to determine serum uric acid levels in Acute Coronary Syndromes (ACS) and to compare the incidence of complications in hyperuricaemic and normouricaemic ACS patients.

**MATERIAL AND METHODS**

This prospective cohort study was conducted in the Department of Medicine in collaboration with Department of Biochemistry, Regional Institute of Medical Sciences (RIMS), Imphal, Manipur, from October 2014 to October 2016. Study was approved by the Institutional Ethical Committee, Regional Institute of Medical Sciences, Imphal and all the participants gave written informed consent prior to the study.

Study population comprised of 146 patients aged >18 years with acute coronary syndromes admitted in ICCU, RIMS, irrespective of race and sex. Acute coronary syndromes include symptomatic ACS, unstable angina, STEMI and NSTEMI. The study participants were divided into 2 groups: 73 patients of ACS with normal serum uric acid levels (normouricaemic) and 73 ACS patients with elevated serum uric acid levels (hyperuricaemic). Patients with symptomatic chronic heart failure, uncontrolled diabetes mellitus, severe kidney and liver diseases, malignancies, brain injury within 3 months before enrolment, pulmonary infections, surgery, trauma or inflammatory conditions within 1 month and pregnant women were excluded from the study.

Each individual enrolled in the study underwent a detailed history taking, general physical examination, systematic examination and routine investigations like complete blood count, liver function test, random blood sugar and uric acid. Five ml of venous blood was collected from each individual in the first 48 hours after admission. Serum uric acid was measured by enzymatic colorimetric method as described by Fossati P et al using Randox kit by Randox series RX Imola Autoanalyser (Manufactured 2007, United Kingdom).

**RESULTS**

Table 1 shows the general characteristics and mean serum uric (SUA) levels in the study groups. There was a male preponderance in the study group (61% and 39% in males and females respectively). Out of the total 146 patients, 67

|                | Normouricaemic | Hyperuricaemic | Total     |
|----------------|----------------|----------------|-----------|
| Sex            |                |                |           |
| Female         | 25(34.2%)      | 32(43.8%)      | 57(39%)   |
| Male           | 48(65.8%)      | 41(56.2%)      | 89(61%)   |
| Smoking        |                |                |           |
| Yes            | 33(45.2%)      | 34(46.6%)      | 67(45.9%) |
| No             | 19(26%)        | 17(23.3%)      | 36(24.7%) |
| Mean SUA ± SD  | 4.43±1.21      | 7.49±0.94      | 5.96±1.88 |

**Table-1:** General characteristics and mean SUA levels in the study groups

| Age in years | Normouricaemic | Hyperuricaemic | Total     |
|--------------|----------------|----------------|-----------|
| <30          | 0(0%)          | 1(1.4%)        | 1(0.7%)   |
| 30-40        | 5(6.8%)        | 4(5.5%)        | 9(6.2%)   |
| 41-50        | 12(16.4%)      | 20(27.4%)      | 32(21.9%) |
| 51-60        | 28(38.4%)      | 32(43.8%)      | 60(41.1%) |
| 61-70        | 23(31.5%)      | 8(11%)         | 31(21.2%) |
| 71-80        | 4(5.5%)        | 8(11%)         | 12(8.2%)  |
| >80          | 1(1.4%)        | 0(0%)          | 1(0.7%)   |
| Total        | 73(100%)       | 73(100%)       | 146(100%) |
| Mean ± SD    | 57.47±10.03    | 55.67±10.75    | 56.57±10.40 |

Samples are age matched with P=0.299

**Table-2:** Age distribution of patients studied

| Killip Class | Normouricaemic | Hyperuricaemic | Total     |
|--------------|----------------|----------------|-----------|
| 1            | 44(60.3%)      | 37(50.7%)      | 81(55.5%) |
| 2            | 22(30.1%)      | 21(28.8%)      | 43(29.5%) |
| 3            | 7(9.6%)        | 11(15.1%)      | 18(12.3%) |
| 4            | 0(0%)          | 4(5.5%)        | 4(2.7%)   |
| Total        | 73(100%)       | 73(100%)       | 146(100%) |

P=0.363, not significant, Fisher Exact test

**Table-3:** Killip Class distribution in two groups of patients studied
C3

Table 4: BMI (kg/m²) distribution in two groups of patients studied

| BMI (kg/m²) | Normouricaemic | Hyperuricaemic | Total |
|------------|----------------|----------------|-------|
| <18.5      | 0(0%)          | 2(2.7%)        | 2(1.4%) |
| 18.5-25    | 54(74%)        | 56(76.7%)      | 110(75.3%) |
| 25-30      | 19(26%)        | 14(19.2%)      | 33(22.6%) |
| >30        | 0(0%)          | 1(1.4%)        | 1(0.7%) |
| Total      | 73(100%)       | 73(100%)       | 146(100%) |
| Mean ± SD  | 24.12±1.99     | 23.33±2.27     | 23.73±2.17 |

P=0.029*, significant, student t test

Table 5: Incidence of arrhythmias, CCF and pulmonary edema (PE) in the two groups of patients studied

|                  | Normouricaemic | Hyperuricaemic | Total  | P value |
|------------------|----------------|----------------|--------|---------|
| Arrhythmias**    | 45.5%          | 20(27.4%)      | 24(16.4%) | <0.001  |
| CCF              | 10(13.7%)      | 17(23.3%)      | 27(18.5%) | 0.136   |
| Pulmonary edema  | 28(38.4%)      | 35(47.9%)      | 63(43.2%) | 0.242   |

P< 0.001**, significant, Chi-square test

Table 6: Outcome at discharge incidence in two groups of patients studied

| Outcome at discharge | Normouricaemic | Hyperuricaemic | Total  | P value |
|----------------------|----------------|----------------|--------|---------|
| <7                   | 50(68.5%)      | 36(49.3%)      | 86(58.9%) |         |
| 7-14                 | 20(27.4%)      | 29(39.7%)      | 49(33.6%) |         |
| >14                  | 3(4.1%)        | 8(11%)         | 11(7.5%) |         |
| Total                | 73(100%)       | 73(100%)       | 146(100%) |         |

P=0.094+, Significant, Fisher Exact test

Figure 1: Clinical Diagnosis in two groups of patients studied

(45.9%) were smokers and 36 (24.7%) used alcohol. The mean SUA level in the study population was 5.96±1.88 mg/dl. Normouricaemic patients had mean SUA levels 4.43±1.21 mg/dl, while mean SUA levels in hyperuricaemic patients was 7.49±0.94 mg/dl.

Table 2 shows that the most common age group in ACS was 51-60 years (41.1%) in both normouricaemic and hyperuricaemic individuals (38.4% and 43.8% respectively) and the mean age in the study population was 56.57±10.40 years (57.47±10.03 in normouricaemic and 55.67±10.75 in hyperuricaemic groups respectively).

Figure 1 shows that the most common clinical diagnosis among the patients with ACS was STEMI/IWMI followed by NSTEMI/LWMI, STEMI/ALWMI, STEMI/ASWMI (36.3%, 15.1%, 12.3% and 11% respectively) comparable across the study population and the least common occurrence was that of Unstable Angina in only one patient with Hyperuricaemia.

Table 3 shows Killip Class Functional Classification across the study groups. Majority of patients belonging to both study groups could be grouped into the Class 1 Killip Functional Classification (55.5%) followed by Killip Class 2 (29.5%) and Killip Class 3 (12.3%), comparable across the study groups. However, Killip Class 4 Functional Classification was observed only in 4 patients belonging to the hyperuricaemic group of individuals (5.5%).

Table 4 shows the relation between BMI and ACS in the study groups. Majority of the patients were categorised into the BMI category 18.5-25 i.e, 110 patients (75.3%); 54 normouricaemic and 56 hyperuricaemic (74% and 76.7% respectively). Mean BMI in normouricaemic and hyperuricaemic individuals was 24.12±1.99 kg/m² and 23.33±2.27 kg/m² respectively.

Table 5 shows the occurrence of arrhythmias, congestive cardiac failure (CCF) and pulmonary edema across the study groups. Arrhythmias occurred in 24 patients (16.4%) in general, out of which 20 patients were hyperuricaemic as compared to 4 patients who were normouricemic (27.4% and 5.5% respectively). It was observed that total 27 patients (18.5%) developed CCF, out of which 17 patients (22.3%) were hyperuricaemic and 10 patients (13.7%) were normouricemic. Pulmonary edema was observed in 63 patients (43.2%), out of which 35 patients were hyperuricaemic and 28 patients were normouricemic (47.9% and 38.4% respectively).

Table 6 charts the outcome at discharge incidence in the study groups. All 146 patients improved during hospital stay, though varying in duration. 86 patients (58.9%) were
discharged within a week of admission, out of which, 50 were normouricaemic while 36 were hyperuricaemic (68.5% and 49.3% respectively). 49 patients (33.6%) were discharged within 2 weeks of admission, wherein, 20 were in the normouricaemic group and 29 in the hyperuricaemic group (27.4% and 39.7% respectively). 11 patients (7.5%) were hospitalized for almost 4 weeks, but eventually discharged, among them 3 were normouricaemic and 8 hyperuricaemic (4.1% and 11% respectively).

Statistical software namely SAS 9.2, SPSS 15.0, Stata 10.1, MedCalc 9.0.1, Systat 12.0 and R environment ver.2.11.1 were used for analysis of the data. Results on continuous measurements were presented on Mean ± SD and results on categorical measurements were presented in number (%). Student t test was used to find the significance of study parameters on continuous scale between two groups on metric parameters. Chi-square/ Fisher Exact test was used to find significance of study parameters on categorical scale between two or more groups.

DISCUSSION

The present study showed that the most common age group at which patients suffered ACS was 51-60 years (41.1%) in both normouricaemic and hyperuricaemic individuals (38.4% and 43.8% respectively) with the mean age 56.5±10.40 years (57.47±10.03 in normouricaemic and 55.67±10.75 in hyperuricaemic groups respectively).

The study observed a male preponderance in the incidence of ACS overall as compared to females (61% vs 39%). However, SUA levels was found to be elevated in females more than in males, which was similar to a study conducted by Short RA et al\(^9\) and Strasak AM et al\(^9\) where females were observed to have higher incidence of hyperuricaemia as compared to males.

Majority of patients belonging to both study groups could be grouped into the Class I Killip Functional Classification (55.5%) followed by Killip Class II (29.5%) and Killip Class III (12.3%), comparable across the study groups. However, Killip Class IV Functional Classification was observed only in 4 patients of the hyperuricaemic group of individuals (5.5%). There were no mortalities in the present study. The findings in this study concur with that conducted by Kojima S et al\(^9\) wherein the study results suggested that hyperuricaemia after AMI is associated with the development of heart failure. Serum uric acid level could, therefore, be considered a suitable marker for predicting AMI-related future adverse events, and the combination of Killip’s class and serum uric acid level after AMI is a good predictor of morbidity and mortality in patients who have AMI.

In the present study, out of the 146 patients studied 45.9% had smoking and 24.7% alcohol use as risk factors and comparable across the study groups. Though considered as significant risk factors for ACS, the results, however, were not statistically significant to correlate the SUA levels to the severity of complications.

There is a common concept that patients with a higher BMI kg/m² are more likely to suffer ACS and CAD. In this study, however, it was observed that patients in the normal BMI range of 18.5-25 kg/m² suffered from ACS with a slightly higher number of patients in the hyperuricaemic group than in the normouricaemic group (76.7 vs 74%). This is in concurrence with a study conducted by Okura T et al\(^9\), wherein, the association of elevated serum uric acid (UA) with cardiovascular events in patients with severe coronary artery stenosis was examined and elevated UA was found to be an independent predictor of cardiovascular events and all-cause mortality in patients with normal BMI ranges.

Arrhythmias, congestive cardiac failure (CCF), pulmonary oedema (PE), stroke and death are proven complications of ACS. In our study, arrhythmias occurred in 24 patients (16.4%) in general, out of which 20 patients were hyperuricaemic as compared to 4 patients who were normouricaemic (27.4% vs 5.5%). Similar findings were seen in a study conducted by Ioachimescu AG et al\(^9\) who evaluated the prognostic value of serum uric acid levels in a large cohort of men and women at high risk of cardiovascular disease. In it, patients with elevated levels of uric acid were found to have more incidences of complications as compared to those who were normouricaemic. However, further studies are required to prove the association as the sample size may not be a representative of the entire population. CCF was observed in 18.5%, out of which hyperuricaemic individuals were more prone to develop CCF than normouricaemic individuals (22.3% vs 13.7%). PE was observed in 43.2% of patients as a whole, however hyperuricaemic patients were found to be at a significantly higher risk of developing PE when compared to normouricaemic patients (47.9% vs 38.4%).

Similarly, in studies conducted by Chen JH et al\(^2\), Jelić-Ivanović Z et al\(^3\), Wang JW et al\(^4\), the investigators also observed higher incidences of Major Adverse Cardiovascular Events (MACE), in hyperuricaemic patients as compared to normouricaemic patients.

In the present study, all 146 patients improved during hospital stay, though varying in duration. Out of which 58.9% were discharged within a week of admission, more in the normouricaemic than hyperuricaemic (68.5% vs 49.3%); 33.6% were discharged within 2 weeks of admission, majority of whom were in the hyperuricaemic group as compared to normouricaemic group (39.7% vs 27.4%); 7.5% were hospitalized for almost 4 weeks, but eventually discharged, among them maximum patients were hyperuricaemic (11% vs 4.1%) and had a protracted course of illness and was statistically significant.

CONCLUSION

The present study showed that complications of ACS such as arrhythmias, CCF, PE occurred more frequently in hyperuricaemic individuals as did the severity of Killip Class functional classification. Majority of the patients in the normouricaemic group had an uneventful hospital stay and recovered earlier as compared to those in the hyperuricaemic group, who experienced a longer duration of hospitalisation with higher incidences of complications. Thus it can be concluded that serum uric acid level, a relatively inexpensive
and widely available biomarker, could be considered a suitable marker for predicting ACS-related future adverse events, and the combination of Killip’s class and serum uric acid level is a good predictor of risk stratification in patients who present with ACS.

REFERENCES

1. Antman EM, Loscalzo J. Ischaemic heart disease. In: Braunwald F, Kasper, Hauser, Longo, Jameson, Loscalzo, editors. Harrison’s Principles of Internal Medicine. 19th ed. USA: The McGraw-Hill companies Inc; 2015;1578-93.
2. Cannon CP, Braunwald E. Non ST-segment elevation acute coronary syndrome (non- ST-segment elevation myocardial infarction and unstable angina). In: Braunwald F, Kasper, Hauser, Longo, Jameson, Loscalzo, editors. Harrison’s Principles of Internal Medicine. 19th ed. USA: The McGraw-Hill companies Inc; 2015;1593-8.
3. Lippi G, Montagnana M, Franchini M. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008;392:1-7.
4. Bickel C, Rapprechjt HJ, Blankenberg S. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12-7.
5. Kojima S, Sakamoto T, Ishihara M. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005;96:489-95.
6. Anker SD, Doehner W, Rauchchaus M. Uric acid and survival in chronic heart failure: validation in metabolic, functional and haemodynamic staging. Circulation 2003;107:1991-7.
7. Yoo TW, Sung KC, Shin HS. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005;69:928–33.
8. Gertler MM, Garu SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Int Med 2008;34:1421-31.
9. Strassak AM, Kelleher CC, Brant LJ. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008;125:232-9.
10. Gur M, Yilmaz R, Demirbug R. Relation of serum uric acid levels with the presence and severity of angiographic coronary artery disease. Angiology 2008;59:166-71.
11. Wu LL, Wu JT. Serum uric acid is a marker of inflammation and a marker predicting the risk of developing CVD, stroke, renal failure and cancer. J Biomed Lab Sci 2008;20:1-6.
12. Goodarznejad H, Anvari MS, Boroumand MA, Karimi A, Abbasi SH, Davoodi G. Hyperuricaemia and the presence and severity of coronary artery disease. Laboratory Medicine 2010;41:40-5.
13. Proctor PH. Uric acid: neuroprotective or neurotoxic? Stroke 2008;39:88-93.
14. Manzano L, Babalis D, Roughton M, Shibata M, Anker SD, Ghio S, et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011;13:528-36.
15. Chen L, Li X, Qiao W, Ying Z, Qin Y, Wang Y, et al. Serum uric acid in patients with acute ST-elevation myocardial infarction. World J Emerg Med 2012;3:35-9.
16. Dharma S, Siswanto BB, Soerianata S, Warded AJ, Jukema JW. Serum uric acid as an independent predictor of cardiovascular event in patients with acute ST elevation myocardial infarction. J Clin Experiment Cardiol 2012;SS5:005.
17. Okafor QH, Collins SP, Jenkins CA, Miller KF, Maron DJ, Naftilan AJ, et al. Relationship between uric acid levels and diagnostic and prognostic outcomes in acute heart failure: The Open Biomarkers J 2012;5:9-15.
18. Fossati P, Principe L, Berti G. Use of N-ethyl-N(2-hydroxy-3-sulphopropyl 3-methylalnine) 4-aminophenazone chromagenic system in direct enzymatic assay of uric acid in serum and urine. Clin Chem 1980;26:227-31.
19. Short RA, Tuttle KR. Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease. A statistical modelling perspective. Semin Nephrol 2005;25:25-31.
20. Okura T, Higaki J, Kurata M, Irita J, Miyoshi KI, Yamazaki T, et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J 2009;73:885-91.
21. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008;58:623-30.
22. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: A chinese cohort study. Arthritis Care & Research. 2009;61:225-32.
23. Jelic-Ivanovic V, Memon L, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Spasic S. Independent association of high serum uric acid concentration with angiographically defined coronary artery disease. Tohoku J Exp Med. 2007;211:369-77.
24. Wang JW, Chen YD, Wang CH, Zhu XL. Correlation of serum uric acid levels with coronary flow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention. Zhonghuayixueyexzhi. 2012;92:3100-3.

Source of Support: Nil; Conflict of Interest: None
Submitted: 06-01-2019; Accepted: 05-03-2019; Published: 18-03-2019